Published in Drug Law Weekly, July 29th, 2008
Under terms of the agreement, Amgen will pay Ortho Biotech $200 million. The after-tax gain of approximately $120 million is expected to be recorded in the results of operations for Johnson & Johnson for the third quarter of 2008.
Ortho Biotech is pleased with the agreement and the pending litigation in New Jersey District Court will be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.